MaxCyte, Inc.
NASDAQ:MXCTMedical - Devices
+$0.05 today
- Market cap
- $129.06M
- Beta
- 1.67
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$0.37
Volume 0.97M
Average 0.95M
MXCT EBITDA Margin
EBITDA as a percentage of revenue.
MaxCyte, Inc.NASDAQ: MXCT
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -38.4%
EBITDA Margin was -38.4% in Q1 FY2026, up 48.1 pp from a year earlier. On a trailing-twelve-month basis it was -107.3%, down 9.8 pp year over year. Over 3 fiscal years it narrowed by 72.7 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -61.8% for the fiscal year ending Dec 2026, up from -119.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -38.4%+75.5 pp QoQ
- Last fiscal yearDec 2025
- -119.6%-25.7 pp YoY
- LTMMar 2026
- -107.3%-9.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +48.1 pp | +5.3 pp | -42.8 pp |
| 1 year | -25.7 pp | +57.7 pp | +83.4 pp |
| 3 years | -72.7 pp | +93.9 pp | +166.6 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -119.6%
- Year-over-year change
- -25.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -119.6% | -25.7pp |
| FY2024 | 2024-12-31 | -93.9% | -12.1pp |
| FY2023 | 2023-12-31 | -81.7% | -34.9pp |
| FY2022 | 2022-12-31 | -46.9% | +2.1pp |
| FY2021 | 2021-12-31 | -49.0% | — |
EBITDA Margin vs competitors
How MXCT compares with its peers on the latest reported figures
- MXCT's LTM Mar 2026 EBITDA Margin of -107.3% is the 5th highest of the 11 companies compared; the peer median is -270.2%.
- Its year-over-year change of -9.8 pp is the 6th highest of 11, against a peer median of -7.2 pp.
- Over three fiscal years its change of -72.7 pp compares with a peer median of +35.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 58.8% | +150.4 pp | -4.3 pp | |
| LTM Mar 2026 | -40.4% | -29.4 pp | +75.4 pp | |
| LTM Mar 2026 | -45.4% | +91.4 pp | +1621.5 pp | |
| LTM Mar 2026 | -46.7% | +22.3 pp | +304.0 pp | |
| LTM Mar 2026 | -107.3% | -9.8 pp | -72.7 pp | |
| LTM Mar 2026 | -200.6% | +96.6 pp | +145.4 pp | |
| LTM Mar 2026 | -339.9% | -229.0 pp | -131.5 pp | |
| LTM Dec 2025 | -376.3% | +15.0 pp | +506.1 pp | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -5021.0% | -1760.3 pp | -3924.4 pp |
| LTM Mar 2026 | -8872.8% | -9159.7 pp | -2521.0 pp | |
| LTM Mar 2026 | -17902.8% | -12192.4 pp | -11194.0 pp | |
| Peer median (excluding MXCT) | -270.2% | -7.2 pp | +35.6 pp | |
Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.89M | 44.26M | 41.29M | 38.63M | 33.03M |
| Cost of Revenue | 3.65M | 5.1M | 4.74M | 7.1M | 6.22M |
| Gross Profit | 30.25M | 39.16M | 36.55M | 31.53M | 26.8M |
| Gross Margin | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Research & Development | 15.41M | 19.51M | 23.82M | 22.23M | 20.82M |
| Selling, General & Admin | 31.68M | 44.48M | 57.04M | 56.35M | 47.04M |
| Operating Expenses | 48.44M | 66.52M | 84.85M | 82.72M | 72.09M |
| Depreciation & Amortization | 1.42M | 2.7M | 4.17M | 4.79M | 5.14M |
| EBITDA | (16.61M) | (20.75M) | (33.75M) | (36.27M) | (39.49M) |
| EBITDA Margin | -49.0% | -46.9% | -81.7% | -93.9% | -119.6% |
| Operating Income | (18.19M) | (27.36M) | (48.3M) | (51.2M) | (45.29M) |
| Operating Margin | -53.7% | -61.8% | -117.0% | -132.5% | -137.1% |
| Interest Income | 150.8K | 3.92M | 10.38M | 10.14M | 7.27M |
| Interest Expense | 1.04M | 126.9K | 0 | 0 | 0 |
| Other Income / Expenses | (893.6K) | 3.79M | 10.38M | 10.14M | 655K |
| Income Before Tax | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Pre-Tax Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.08M) | (23.57M) | (37.92M) | (41.06M) | (44.63M) |
| Net Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| EPS (Basic) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| EPS (Diluted) | (0.22) | (0.19) | (0.37) | (0.39) | (0.42) |
| Weighted Avg Shares | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
| Weighted Avg Shares (Diluted) | 90.62M | 101.7M | 103.27M | 104.85M | 106.43M |
MaxCyte, Inc.
NASDAQ:MXCT
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.